熱門資訊> 正文
Neoleukin prices equity offering at $8.40
2019-12-18 11:05
Neoleukin Therapeutics (NASDAQ:NLTX) prices its public offering of 8,925,000 common shares at $8.40 per share, for expected gross proceeds of ~$75M.
Closing date is December 20.
Underwriters' over-allotment is an additional 1,338,750 shares.
Net proceeds will be used to advance development of NL-201, to expand itsde novoprotein design technology, to fund working capital and for general corporate purposes.
Shares are up2%premarket.
Click to subscribe to real-time analytics on NLTX
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
